Abstract Number: 1531 • 2015 ACR/ARHP Annual Meeting
The Changing Face of Septic Arthritis Complicating Rheumatoid Arthritis in the Era of Biotherapies. Retrospective Single-Center Study over 35 Years
Background/Purpose: Rheumatoid arthritis (RA) is a risk factor for septic arthritis (SA), and anti-TNF therapy doubles the risk of SA. The purpose of this study…Abstract Number: 1567 • 2015 ACR/ARHP Annual Meeting
Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting
Background/Purpose: Previous studies combining immunosuppressive biologics have shown an increased risk of infections. Few studies have examined the risk of infection with concurrent use of…Abstract Number: 430 • 2015 ACR/ARHP Annual Meeting
Adoption of Treat to Target Management in the Context of Achievable Goals and Satisfaction in RA
Background/Purpose: The approach of setting disease activity targets and adjusting therapy appropriately to achieve the target has been proven to optimize outcomes in Rheumatoid Arthritis…Abstract Number: 1980 • 2015 ACR/ARHP Annual Meeting
Tocilizumab in Giant Cell Arteritis: A Multicentre Open-Label Study in France
Background/Purpose: To report the French experience on the efficacy and safety of tocilizumab (TCZ) in patients with giant cell arteritis (GCA) and outcome after treatment…Abstract Number: 432 • 2015 ACR/ARHP Annual Meeting
Additional Intensive Treatment for Rheumatoid Arthritis Patients with Positive Power Doppler Signals Reduce the Radiological Joint Damage Even after Achieving Clinical Remission -SCRUM Study-
Background/Purpose: The latest recommendations for the treatment of rheumatoid arthritis (RA) focus on the achievement of clinical remission. However, joints with subclinical positive power Doppler…Abstract Number: 2059 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Inhibitor Tapering Induced Radiographic Progression Is Driven By Weighted Mean Disease Activity over Time, Not Flaring or Lower TNFi Exposition
Background/Purpose: DRESS, a randomized controlled strategy trial (RCT)1investigating disease activity guided tapering of etanercept and adalimumab compared to usual care in RA patients, indicated that…Abstract Number: 446 • 2015 ACR/ARHP Annual Meeting
Low Disease Activity at 12 Weeks and 24 Weeks Is Predictive of Normalized Health-Related Quality of Life in Methotrexate-Experienced Patients with Active Rheumatoid Arthritis Treated with Intravenous Golimumab Plus Methotrexate
Background/Purpose: Previous analyses in patients (pts) with rheumatoid arthritis (RA) have evaluated the relationship between controlling disease activity and achieving long-term improvements in health-related quality…Abstract Number: 2145 • 2015 ACR/ARHP Annual Meeting
Ixekizumab Improves Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease associated with psoriasis, peripheral arthritis, enthesitis, dactylitis, and spondylitis. PsA has a significant negative impact…Abstract Number: 464 • 2015 ACR/ARHP Annual Meeting
Biologic Therapy Treatment Complications in the Alberta Aboriginal Population with Rheumatoid Arthritis
Biologic Therapy Treatment Complications in the Alberta Aboriginal Population with Rheumatoid Arthritis Background/Purpose: Aboriginal people with rheumatoid arthritis (RA) have more severe disease and an…Abstract Number: 2336 • 2015 ACR/ARHP Annual Meeting
Literature Review of Patient Reported Outcome and Health Related Quality of Life Measures for Biologic Therapies in the Management of Psoriatic Arthritis and Ankylosing Spondylitis
Background/Purpose: Psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are chronic progressive conditions with substantial humanistic burden on patients and care givers. A variety of instruments,…Abstract Number: 500 • 2015 ACR/ARHP Annual Meeting
Ofatumumab for Rheumatoid Arthritis: A Cochrane Systematic Review and Meta-Analysis
Background/Purpose: Ofatumumab is a unique anti-CD20 monoclonal antibody with its epitope more proximal and distinct from the epitope recognized by rituximab or by other anti-CD20…Abstract Number: 2522 • 2015 ACR/ARHP Annual Meeting
High Risk of Flares during Pregnancy in Women with Rheumatoid Arthritis Who Discontinue Treatment with TNF Inhibitors at Conception
Background/Purpose: Optimal treatment of women with Rheumatoid Arthritis (RA) during pregnancy remains a challenge, mainly due to safety concerns. TNF inhibitors (TNFi) are now routinely…Abstract Number: 2407 • 2014 ACR/ARHP Annual Meeting
Early Treatment in Rheumatoid Arthritis and Its Effect on Patient Outcomes
Background/Purpose: It is generally thought that the early treatment of patients with rheumatoid arthritis (RA) leads to improved patient outcomes over time. Our study aims…Abstract Number: 1164 • 2014 ACR/ARHP Annual Meeting
Inequity: Level of Education Is Associated with Access to Biologic Dmards Even in a Country with Highly Developed Social Welfare (Norway)
Background/Purpose Biologic DMARDs (bDMARDs) have greatly improved the outcome of rheumatoid arthritis (RA). Investigating possible inequities in access to bDMARDs across socio-economic factors is important,…Abstract Number: 2380 • 2014 ACR/ARHP Annual Meeting
Durability of First Biologic Is Not Influenced By Initial/Early DAS28
Background/Purpose: The Ontario Best Practices Research Initiative (OBRI) collects data on RA treatment in a real-world setting. Patients are enrolled and prospectively followed to…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 14
- Next Page »